Maverick Capital’s Emergent Biosolutions EBS Stock Holding History

Maverick Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,858	Closed	-$293K	–	414
2021 Q3	$293K	Buy	5,858 +5,569	+1,927%	+$337K	﹤0.01%	498
2021 Q2	$18K	Buy	+289	New	+$18.6K	﹤0.01%	657
2021 Q1	–	Sell	-2,364	Closed	-$212K	–	756
2020 Q4	$212K	Buy	+2,364	New	+$217K	﹤0.01%	520

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital's EBS Position: Q4 2021 in Review

Maverick Capital sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 5,858 shares — an estimated $293K sold.

Maverick Capital first reported a position in EBS in Q4 2020 and held it in 3 quarters. The position peaked at $293K in Q3 2021. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

Maverick Capital reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
Maverick Capital sold 5,858 Emergent Biosolutions shares in Q4 2021, an estimated $293K.
Maverick Capital first reported a position in Emergent Biosolutions in Q4 2020 and held it in 3 quarters.
Maverick Capital's Emergent Biosolutions position peaked at $293K in Q3 2021.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.